62 related articles for article (PubMed ID: 18605086)
21. Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Nagy H; Goda K; Fenyvesi F; Bacsó Z; Szilasi M; Kappelmayer J; Lustyik G; Cianfriglia M; Szabó G
Biochem Biophys Res Commun; 2004 Mar; 315(4):942-9. PubMed ID: 14985103
[TBL] [Abstract][Full Text] [Related]
22. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
Li B; Ye T; Zhao L; Li DH; Gou XH; Zhao LY; Han L; Chen L; Yan LN; Gong JP
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
[TBL] [Abstract][Full Text] [Related]
23. Detection of P-glycoprotein-mediated multidrug resistance against anthelmintics in Haemonchus contortus using anti-human mdr1 monoclonal antibodies.
Kerboeuf D; Guégnard F; Vern YL
Parasitol Res; 2003 Sep; 91(1):79-85. PubMed ID: 12898231
[TBL] [Abstract][Full Text] [Related]
24. Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.
Ibrahim S; Peggins J; Knapton A; Licht T; Aszalos A
Anticancer Res; 2001; 21(2A):847-56. PubMed ID: 11396174
[TBL] [Abstract][Full Text] [Related]
25. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.
Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY
Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879
[TBL] [Abstract][Full Text] [Related]
26. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
27. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.
Hu XF; Slater A; Rischin D; Kantharidis P; Parkin JD; Zalcberg J
Br J Cancer; 1999 Feb; 79(5-6):831-7. PubMed ID: 10070877
[TBL] [Abstract][Full Text] [Related]
28. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
29. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
30. Detection of P-glycoprotein with a rapid flow cytometric functional assay using Fluo-3: evaluation of sensitivity, specificity and feasibility in multiparametric analysis.
Van Acker KL; De Greef C; Eggermont J; Zhang P; Vandenberghe P; Boogaerts MA
Leukemia; 1995 Aug; 9(8):1398-406. PubMed ID: 7643631
[TBL] [Abstract][Full Text] [Related]
31. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients.
Taheri M; Mahjoubi F; Omranipour R
Genet Mol Res; 2010 Jan; 9(1):34-40. PubMed ID: 20082268
[TBL] [Abstract][Full Text] [Related]
32. Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
Findling-Kagan S; Sivan H; Ostrovsky O; Nagler A; Galski H
Leuk Res; 2005 Apr; 29(4):407-14. PubMed ID: 15725475
[TBL] [Abstract][Full Text] [Related]
33. Tissue distribution of the human MDR3 P-glycoprotein.
Smit JJ; Schinkel AH; Mol CA; Majoor D; Mooi WJ; Jongsma AP; Lincke CR; Borst P
Lab Invest; 1994 Nov; 71(5):638-49. PubMed ID: 7734012
[TBL] [Abstract][Full Text] [Related]
34. [Assessment of P glycoprotein expression by immunocytochemistry and flow cytometry coupled with functional efflux analysis: application to acute myeloid leukemia].
Poulain S; Lepelley P; Cambier N; Wattel E; Fenaux P; Cosson A
Ann Biol Clin (Paris); 1999; 57(5):595-600. PubMed ID: 10518062
[TBL] [Abstract][Full Text] [Related]
35. Measurement of P-glycoprotein Function.
Broxterman HJ
Methods Mol Med; 1999; 28():53-61. PubMed ID: 21374027
[TBL] [Abstract][Full Text] [Related]
36. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network.
Huet S; Marie JP; Gualde N; Robert J
Cytometry; 1998 Dec; 34(6):248-56. PubMed ID: 9879641
[TBL] [Abstract][Full Text] [Related]
37. [Parameters of specific antibody interaction with P-gp in T-cell leukemia Jurkat cells].
Bogush TA; Dudko EA; Bogush EA; Baryshnikov AIu
Antibiot Khimioter; 2009; 54(1-2):3-9. PubMed ID: 19499709
[TBL] [Abstract][Full Text] [Related]
38. Genetic analysis of the multidrug transporter.
Gottesman MM; Hrycyna CA; Schoenlein PV; Germann UA; Pastan I
Annu Rev Genet; 1995; 29():607-49. PubMed ID: 8825488
[TBL] [Abstract][Full Text] [Related]
39. [Detection of P-glycoprotein in squamous cell carcinoma of larynx].
Shi L; Guo M
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1997 Dec; 32(6):336-8. PubMed ID: 10743105
[TBL] [Abstract][Full Text] [Related]
40. Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
Fattori S; Becherini F; Cianfriglia M; Parenti G; Romanini A; Castagna M
Virchows Arch; 2007 Jul; 451(1):81-7. PubMed ID: 17593388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
